Fulcrum Therapeutics (FULC, Financial) has received a significant boost as Cantor Fitzgerald has upgraded its rating on the stock from Neutral to Overweight. This upgrade reflects a growing confidence in the company's future prospects.
The analyst responsible for this upgrade, Kristen Kluska, has announced a new price target of $10.00 USD for Fulcrum Therapeutics. This marks the first time a price target has been specified by Cantor Fitzgerald for FULC, providing investors with a new outlook on the stock's potential.
Fulcrum Therapeutics, listed on the NASDAQ, focuses on developing treatments targeting the root causes of genetically defined diseases. The upgrade and new price target suggest promising developments for the company moving forward.
Investors may find this upward revision by Cantor Fitzgerald a pivotal moment for Fulcrum Therapeutics as it strives to enhance its market position and deliver on its therapeutic strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Fulcrum Therapeutics Inc (FULC, Financial) is $6.00 with a high estimate of $12.00 and a low estimate of $2.00. The average target implies an upside of 0.93% from the current price of $5.95. More detailed estimate data can be found on the Fulcrum Therapeutics Inc (FULC) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Fulcrum Therapeutics Inc's (FULC, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Fulcrum Therapeutics Inc (FULC, Financial) in one year is $39.01, suggesting a upside of 556.18% from the current price of $5.945. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Fulcrum Therapeutics Inc (FULC) Summary page.
